Literature DB >> 6293115

Obstruction of the inferior vena cava in the hepatic portion and hepatocellular carcinoma.

S Nakamura, Y Takezawa.   

Abstract

High incidence of hepatocellular carcinoma in patients with obstruction of the inferior vena cava in the hepatic portion (Budd-Chiari syndrome) was previously pointed out by us from the review of Japanese literature of autopsied cases. This was confirmed by the follow-up study of 16 patients with obstruction of the inferior vena cava in the hepatic portion hospitalized in 1958 to 1974. Follow-up information was available on 13 of the 16 patients. Deaths due to hepatocellular carcinoma occurred in 6 patients (46%), and those due to other causes in 4 patients (31%). Three patients were alive. Hepatocellular carcinoma occurred most frequently in the patients who were found to have obstruction of the inferior vena cava at less than 44 years of age and were followed up for more than 10 years.

Entities:  

Mesh:

Year:  1982        PMID: 6293115     DOI: 10.1620/tjem.138.119

Source DB:  PubMed          Journal:  Tohoku J Exp Med        ISSN: 0040-8727            Impact factor:   1.848


  4 in total

Review 1.  Liver cirrhosis in hepatic vena cava syndrome (or membranous obstruction of inferior vena cava).

Authors:  Santosh Man Shrestha
Journal:  World J Hepatol       Date:  2015-04-28

2.  Liver cirrhosis and hepatocellular carcinoma in hepatic vena cava disease, a liver disease caused by obstruction of inferior vena cava.

Authors:  Santosh Man Shrestha
Journal:  Hepatol Int       Date:  2009-01-23       Impact factor: 6.047

Review 3.  Budd-Chiari syndrome/hepatic venous outflow tract obstruction.

Authors:  Dominique-Charles Valla
Journal:  Hepatol Int       Date:  2017-07-06       Impact factor: 6.047

4.  Angiotensin II represses Npr1 expression and receptor function by recruitment of transcription factors CREB and HSF-4a and activation of HDACs.

Authors:  Kiran K Arise; Prerna Kumar; Renu Garg; Ramachandran Samivel; Hanqing Zhao; Krishna Pandya; Christian Nguyen; Sarah Lindsey; Kailash N Pandey
Journal:  Sci Rep       Date:  2020-03-09       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.